CliffBio
small molecule

GENTACIDIN

GENTAMICIN SULFATE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameGENTACIDIN
Active ingredientGENTAMICIN SULFATE
StrengthEQ 0.3% BASE
Dosage formOINTMENT
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 1984
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.